PPARδ and PPARγ agonists also have shown benefits in experimental models of SCI, TBI and stroke (McTigue et al., 2007; Yi et al., 2008; Allahtavakoli et al., 2009; Sauerbeck et al., 2011; Thal et al., 2011; Villapol et al., 2012). Here, PPARG is linked to Stroke.